The Uromigos

Episode 517: Casdatifan Clinical Data in RCC and Translational Correlates

Episode 516: The Influence of Hypoxia on Response and Resistance in RCC

Episode 515: PROTEUS - A Reflection on the Data and Controversies with Neha Vapiwala

Episode 514: Artificial Intelligence in Cancer Drug Development

Episode 513: Trials and Tribulations of Investigator-initiated Research

Episode 512: ENZA-P Nature Medicine translational data

Episode 510: ADCs in Prostate Cancer

Episode 509: ASCO 2026 Review

Episode 508: ASCO 2026 Plenary - PROTEUS: ADT +/- Apalutamide in high-risk Localized Prostate Cancer

Episode 507: ASCO 2026 - TALAPRO-3

Episode 506: ASCO 2026 - How do we measure quality of life in GU patients?

Episode 505 : ASCO 2026 - RAMPART

Episode 504: ASCO 2026 - ADC Drug Development in Urothelial Cancer

Episode 499: APCCC 2026 - Radioligands in Prostate Cancer

Episode 503: ASCO 2026 Preview

Episode 502: AUA 2026 and FDA bladder cancer meeting

Episode 501: APCCC 2026 - Biochemically-relapsed Prostate cancer

Episode 500: RAS Inhibition in Pancreatic Cancer (yes this is the Uromigos podcast..)

Episode 498: APCCC 2026 - mCRPC

Episode 497: Reflections on the capivasertib ODAC

Episode 496: APCCC 2026 - mHSPC Landscape

Episode 495: APCCC 2026 - Locally-advanced Prostate Cancer

Episode 494: Duration of EVP in Multiple Urothelial Cancer Settings / Paper of the Month PPARG Inverse Agonist

Episode 493: The Role of Chemotherapy in mHSPC

Episode 492: Novel Biomarkers and Targets in Germ Cell Tumors

Episode 490: Systemic Therapy Only in Patients wtih MIBC

Episode 489: Live Podcast From EAU

Episode 487: ASCO GU 2026 recap

Episode 486: ctDNA and utDNA Data in Peri-operative Urothelial cancer

Episode 485: ASCO GU 2026 - LITESPARK 011: Len/Belzu vs Cabo

Episode 484: ASCO GU 2026 - LITESPARK 022: Adjuvant Pembro + Belzutifan in RCC

Episode 482: ASCO GU 2026 - SUNRISE 2

Episode 483: ASCO GU 2026 - KEYNOTE B15: Neoadjuvant EVP vs Gem/Cis in Cis-eligible MIBC

Episode 480: ASCO GU 2026 - PEACE-3 and BRCAway Final OS Results

Episode 479: Does the Timing of IO Infusion Impact Clinical Outcomes? A Critical Analysis

Episode 478: Prostate Cancer Working Group 4 (PCWG 4) criteria

Episode 476: ASCO GU 2026 Preview

Episode 475: Depth of Response and Overall Survival for IO-based Regimens in mRCC: Results of an FDA Analysis

Episode 474: Uromigos Shorts - IO-refractory Urothelial Cancer

Episode 473: Uromigos Shorts - EMBARK and BCR Prostate Cancer

Episode 472: Uromigos Shorts - Variant Histology Bladder Cancer

Episode 471: Uromigos Shorts - ADCs and BiTEs in Prostate Cancer

Episode 470: Bladder Cancer Year in Review

Episode 469: Prostate Cancer year in Review

Episode 468: RCC Year in Review

Episode 442: The History of ARPI Development in Prostate Cancer

Episode 466: #UromigosLive 2025 - Novel Therapy in mRCC

Episode 465: #UromigosLive 2025 - Adjuvant Therapy in RCC

Episode 464: #UromigosLive 2025 - The Evolving Landscape of mHSPC

Episode 459: #UromigosLive 2025 - Radioligands in Prostate Cancer